Cadrenal Therapeutics CEO Quang Pham Sells 22,385 Shares Under 10b5-1 Plan

Quang X. Pham, Chairman, CEO and Interim CFO of Cadrenal Therapeutics, Inc. (CVKD), filed a Form 4 disclosing sales of 22,385 shares of common stock over three consecutive days from June 8-10, 2026. The sales were executed under a Rule 10b5-1 trading plan adopted on September 25, 2025. Pham sold 5,893 shares at a weighted average price of $4.38 on June 8, 12,992 shares at $4.06 on June 9, and 3,500 shares at $4.21 on June 10. Following these transactions, Pham's direct holdings decreased to 150,839 shares. Additionally, he indirectly holds 200,000 shares through The PVBQ Living Trust, where he serves as trustee with sole voting and dispositive power. The sales represent a significant reduction in his direct ownership position while maintaining substantial indirect holdings through the trust.